laboratory biomarker analysis: Laboratory results will be analysed to identify disease related biomarkers.
Genetic analysis: Gene sequencing results will be analysed to identify disease related mutations.
Study summary
The knowledge on the rare type of pulmonary hypertension which can not be explained by left heart disease, respiratory disease or congenital heart disease is very limited. Investigators aim to setup a national registration study for the rare type of pulmonary hypertension, to understand the natural history, survival, progression, genetic and environmental contributions to disease.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Participant is willing and able to give informed consent for participation in the study.
* Patients diagnosed as idiopathic pulmonary artery hypertension, hereditary pulmonary artery hypertension, hereditary hemorrhagic telangiectasia associated pulmonary artery hypertension, pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis associated pulmonary artery hypertension, cavernous transformation of portal vein associated pulmonary artery hypertension, special type of congenital heart disease associated pulmonary artery hypertension, chronic thromboembolism pulmonary hypertension.
* All patients should have undergone right heart catheterization, diagnosed according to the guideline.
Exclusion Criteria:
The participant may not enter the study if ANY of the following apply:
* Patients unwilling or unable to provide written consent for participation in the study.
* Not suffering from the rare type of pulmonary artery hypertension;
Inclusion criteria-Controls
* Participant is willing and able to give informed consent for participation in the study.
* Self-reported to be healthy
Primary outcome measure(s)
Survival Rate of Participants — up to 10 years, at 12 months interval
Lung transplantation — up to 10 years, at 12 months interval
Change in New York Heart Association (NYHA) functional class — up to 10 years, at 3 months interval
Change in 6 mint walk distance — up to 10 years, at 3 months interval
Trial sites (1)
Facility
City
Region
Status
Chinese Academy of Medical Sciences Fuwai Hospital and Peking Union Medical College Hospital
Beijing
Beijing Municipality
Recruiting
More China National Center for Cardiovascular Diseases trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.